Equities Analysts Issue Forecasts for CORT Q1 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - HC Wainwright lowered their Q1 2025 earnings per share estimates for Corcept Therapeutics in a research report issued on Thursday, February 27th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $0.16 for the quarter, down from their prior estimate of $0.55. HC Wainwright has a "Buy" rating and a $115.00 price objective on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics' Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.57 EPS, FY2025 earnings at $1.93 EPS, FY2026 earnings at $3.80 EPS, FY2027 earnings at $6.26 EPS and FY2028 earnings at $7.34 EPS.

CORT has been the topic of a number of other reports. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a "buy" rating in a research note on Thursday, January 30th. Piper Sandler lifted their target price on Corcept Therapeutics from $67.00 to $78.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Finally, StockNews.com lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.75.

Remove Ads

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded down $1.19 during midday trading on Monday, reaching $54.30. 1,679,053 shares of the company traded hands, compared to its average volume of 1,026,068. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $75.00. The stock has a 50-day moving average price of $60.27 and a 200 day moving average price of $52.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The company has a market cap of $5.73 billion, a price-to-earnings ratio of 43.10 and a beta of 0.58.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Corcept Therapeutics by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company's stock worth $509,726,000 after purchasing an additional 109,294 shares in the last quarter. Parallel Advisors LLC grew its stake in Corcept Therapeutics by 0.4% during the 4th quarter. Parallel Advisors LLC now owns 3,829,632 shares of the biotechnology company's stock valued at $192,975,000 after acquiring an additional 15,908 shares in the last quarter. State Street Corp grew its stake in Corcept Therapeutics by 0.6% during the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock valued at $162,871,000 after acquiring an additional 19,893 shares in the last quarter. Geode Capital Management LLC grew its stake in Corcept Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company's stock valued at $110,108,000 after acquiring an additional 99,470 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Corcept Therapeutics by 4.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company's stock valued at $82,889,000 after acquiring an additional 64,321 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company's stock.

Insider Buying and Selling

In related news, insider Sean Maduck sold 18,303 shares of Corcept Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $60.69, for a total value of $1,110,809.07. Following the transaction, the insider now owns 85,622 shares of the company's stock, valued at approximately $5,196,399.18. This trade represents a 17.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $68.08, for a total value of $149,776.00. The disclosure for this sale can be found here. Insiders have sold a total of 47,827 shares of company stock valued at $2,688,486 over the last three months. Company insiders own 20.50% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.